However, poor prognosis (with a median survival of 12–16 months) was associated with the presence of EGFR amplification or TERT promoter mutations (TERTp-mut), and TERTp-mut is a powerful independent marker in GBM (unassociated with IDH), as is a low level of EGFR ligands [107]. This evidence concerns the gene IDH2 and glioblastoma.